Australian Deal Tracker
22 deal(s) tracked
Largest deal tracked Brookfield & EIG consortium → Origin EnergyQ2 2026
Global healthcare insurer Bupa agreed to buy Partnered Health Group, a network of 68 primary care and 3 urgent care clinics, from private equity firm Quadrant for about A$300m. Still needs ACCC and Foreign Investment Review Board clearance.
UK retail group Frasers, which already owned about 22.9% of Australian footwear retailer Accent Group, launched a full unconditional cash takeover offer at A$0.65/share, valuing the remaining shares at about A$316m. Unresolved as of this writing, with the offer period running to 30 July 2026.
US consumer health company Prestige Consumer Healthcare bought Australian therapeutic skincare business LaCorium Health (Dermal Therapy, Flexitol, Crampeze) for about US$150m (~A$225m), completing the deal in July 2026.
IFM Investors launched a hostile takeover of toll-road operator Atlas Arteria, raising its offer to A$5.10/share (A$7.4bn) and ultimately closing with 67.43% of the register.
Q1 2026
South African gold miner Pan African Resources agreed to acquire ASX-listed explorer Emmerson Resources in an all-share deal worth about A$311m.
Magellan Financial Group merged with investment bank Barrenjoey Capital Partners in a deal valuing Barrenjoey at about A$1.62bn, creating a diversified A$45bn financial services group.
US telehealth company Hims & Hers agreed to buy Australian digital health company Eucalyptus for up to US$1.15bn (~A$1.7bn), completing the deal in June 2026.
A Macquarie Asset Management-led consortium (with UniSuper and Pontegadea as co-investors) agreed to buy ports and logistics operator Qube for A$5.20/share, a 28% premium, valuing the business at A$11.7bn.
Energy Fuels signed a Scheme Implementation Deed to buy rare earths producer Australian Strategic Materials for around US$299m (~A$450m).
SGH and US steelmaker Steel Dynamics proposed splitting up BlueScope: SGH would keep BlueScope's Australian and Asian operations while Steel Dynamics took the North American business. Unresolved as of mid-2026 after four rejections from BlueScope's board.
2025
Brookfield and GIC agreed to take Australia and New Zealand's largest self-storage operator private at A$2.86/unit, in what was described as the largest-ever take-private of an ASX-listed REIT; the deal completed on 8 May 2026.
Caterpillar agreed to acquire Brisbane-based mining software company RPMGlobal Holdings for AUD 5.00/share (A$1.123bn total), completing the acquisition in February 2026.
TPG Capital's Asia-focused private equity division proposed a board-recommended take-private of ASX-listed automotive SaaS company Infomedia at A$1.72/share, an equity value of about A$651m.
CC Capital and OneIM signed a Scheme Implementation Deed to acquire Insignia Financial, Australia's largest diversified wealth manager, at A$4.80/share in cash. Insignia formally delisted from the ASX on 29 April 2026.
Soul Patts and Brickworks merged via a new holding company ("TopCo"), unwinding a complex 56-year cross-shareholding between the two companies. Reported deal size varies by measure (around $12.7-14bn); the schemes became legally effective in September 2025.
Pacific Equity Partners, via its Sherwood BidCo vehicle, took building-restoration services company Johns Lyng Group private at A$4.00/share; the scheme was implemented on 23 October 2025.
Gold Fields agreed to acquire its 50:50 joint venture partner Gold Road Resources at the Gruyere gold mine in Western Australia via a scheme implementation deed, completing in late 2025.
CoStar Group, which had already bought a ~17% stake in Domain in February 2025, agreed to acquire the rest of the Australian property marketplace by scheme of arrangement at A$4.43/share, completing in August 2025.
Ramelius Resources agreed to acquire fellow gold miner Spartan Resources in a cash-and-scrip deal, creating what was described as the third-largest ASX gold producer; new Ramelius shares began trading on 1 August 2025.
Cosette Pharmaceuticals agreed to acquire Mayne Pharma for about US$430m (~A$615m), aiming to combine both companies' women's health and dermatology portfolios — but the deal was later terminated following a court ruling and disputes over alleged breaches.